Therapeutically Targetable Mutational Landscape of Anaplastic Thyroid Cancer - PubMed
5 hours ago
- #Targeted Therapy
- #Anaplastic Thyroid Cancer
- #Mutational Landscape
- Anaplastic thyroid cancer (ATC) is a rare and highly aggressive malignancy with limited treatment options.
- Currently, FDA-approved targeted therapies for ATC are limited to BRAF V600E mutations and NTRK fusions.
- The study analyzed 350 ATC tumor samples from the AACR Project GENIE database to identify somatic pathogenic gene variants (PGVs).
- PGVs were found in MAPK pathway genes (57.7%), PI3K/Akt/mTOR pathway genes (26.6%), HRD-associated genes (8.0%), and MMR-associated genes (3.7%).
- 72% of ATC tumors harbored at least one PGV in potentially targetable pathways.
- The findings support biomarker-driven basket trials for targeted therapies in ATC.